Cargando…
Long-Term Safety, Clinical and Immunological Outcomes in Primary Membranous Nephropathy with Severe Renal Impairment Treated with Cyclophosphamide and Steroid-Based Regimen
INTRODUCTION AND AIMS: Therapy of primary membranous nephropathy (PMN) with progressive advanced kidney dysfunction is challenging with limited literature and no clear therapeutic strategies. This is due to the scant evidence of effectiveness and uncertainty around the risk-benefit profile of immuno...
Autores principales: | Ragy, Omar, Hamilton, Patrick, Pathi, Anjali, Ahmed, Adil Abdalla Mohamed, Mitra, Sandip, Kanigicherla, Durga A.K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126738/ https://www.ncbi.nlm.nih.gov/pubmed/37113496 http://dx.doi.org/10.1159/000529605 |
Ejemplares similares
-
Can use of the serum anti-PLA(2)R antibody negate the need for a renal biopsy in primary membranous nephropathy?
por: Ragy, Omar, et al.
Publicado: (2023) -
Thromboembolism in nephrotic syndrome: controversies and uncertainties
por: Parker, Kathrine, et al.
Publicado: (2023) -
PLA2R Antibody Does Not Outperform Conventional Clinical Markers in Predicting Outcomes in Membranous Nephropathy
por: Ragy, Omar, et al.
Publicado: (2023) -
The investigative burden of membranous nephropathy in the UK
por: Hamilton, Patrick, et al.
Publicado: (2019) -
A Case of IgG4-Related Disease and Membranous Nephropathy Associated with Thrombospondin Type-1 Domain-Containing 7A
por: Hum, Ryan Malcolm, et al.
Publicado: (2022)